Activation of the p38 pathway by a novel monoketone curcumin analog, EF24, suggests a potential combination strategy

Biochemical Pharmacology

Volumn 80, Issue 9, 2010, Pages 1309-1316

  Thomas, Shala L ^a   Zhao, Jing ^b   Li, Zijian ^b   Lou, Bin ^b   Du, Yuhong ^b   Purcell, Jamie ^a   Snyder, James P ^a   Khuri, Fadlo R ^b   Liotta, Dennis ^a   Fu, Haian ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Curcumin analogs; EF24; Lung cancer; P38; P38 inhibitors

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTINEOPLASTIC AGENT; EF24; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 3,5-BIS(2-FLUOROBENZYLIDENE)PIPERIDIN-4-ONE; BENZYLIDENE DERIVATIVE; IMIDAZOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE P38; PIPERIDONE DERIVATIVE; PYRIDINE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL VIABILITY; CYTOTOXICITY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; UPREGULATION; ANTAGONISTS AND INHIBITORS; DRUG COMBINATION; DRUG EFFECTS; LUNG NEOPLASMS; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZYLIDENE COMPOUNDS; CELL LINE, TUMOR; DRUG THERAPY, COMBINATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; IMIDAZOLES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PIPERIDONES; PYRIDINES;

EID: 77956649898     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.06.048     Document Type: Article

References (40)

1. Aggarwal B.B., Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 2009, 30(February (2)):85-94.
2. Gururaj A.E., Beladkavadi M., Venkatesh D.A., Marme D., Salimath B.P. Molecular mechanisms of anti-angiogenic effect of curcumin. Biochem Biophys Res Commun 2002, 297(October 4 (4)):934-942.
3. Duvoix A., Balsius R., Delhalle S., Schnekenburger M., Morceau F., Henry E., et al. Chemopreventative and therapeutic effect of curcumin. Cancer Lett 2005, 223(June 8 (2)):181-190.
4. Cheng A.L., Hsu C.H., Lin J.K., Hsu M.M., Ho Y.F., Shen T.S., et al. Phase I clinical trial of curcumin, a chemopreventative agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001, 21:2895-2900.
5. Sharma R.A., Euden S.A., Platton S.L., Cooke D.N., Shafayat A., Hewitt H.R., et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004, 10(October 15 (20)):6847-6854.
6. Adams B.K., Ferstl E.M., Davis M.C., Herold M., Kurtkaya S., Camalier R.F., et al. Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorg Med Chem 2004, 12(July 15 (14)):3871-3883.
7. Adams B.K., Cai J., Armstrong J., Herold M., Lu Y.J., Sun A., et al. EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anticancer Drugs 2005, 16(March (3)):263-275.
8. Singh S., Aggarwall B.B. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem 2001, 270:24995-25000.
9. Li L., Aggarwall B.B., Shishodia S., Abbruzzese J., Kurkrock R. Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 2004, 101(November 15 (10)):2351-2362.
10. Vanden Berghe W., Plaisance S., Boone E., De Bosscher K., Schmitz M.L., Fiers W., et al. p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kappaB p65 transactivation mediated by tumor necrosis factor. J Biol Chem 1998, 273(February 6 (6)):3285-3290.
11. Tuyt L.M., Dokter W.H., Birkenkamp K., Koopmans S.B., Lummen C., Kruijer W., et al. Extracellular-regulated kinase 1/2, Jun N-terminal kinase, and c-Jun are involved in NF-kappa B-dependent IL-6 expression in human monocytes. J Immunol 1999, 162(April 15 (8)):4893-4902.
12. Raingeaud J., Gupta S., Rogers J.S., Dickens M., Han J., Ulevitch R.J., et al. Pro-inflammatory cytokines and environmental stress casue p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 1995, 270(March 31 (13)):7420-7426.
13. Johnson G.L., Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002, 298(December 6 (5600)):1911-1912.
14. Madrid L.V., Mayo M.W., Reuther J.Y., Baldwin A.S. Akt stimulates the trasactivation potential of the RelA/p65 Subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38. J Biol Chem 2001, 276(June 1 (22)):18934-18940.
15. Enslen H., Raingeaud J., Davis R.J. Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinases MKK3 and MKK6. J Biol Chem 1998, 273(January 16 (3)):1741-1748.
16. Keller D., Zeng X., Li X., Kapoor M., Iordanov M.S., Taya Y., et al. The p38MAPK inhibitor SB203580 alleviates ultraviolet-induced phosphorylation at serine 389 but not serine 15 and activation of p53. Biochem Biophys Res Commun 1999, 261(August 2 (2)):464-471.
17. Sanchez-Prieto R., Rojas J.M., Taya Y., Gutkind J.S. A role for the p38 mitogen-activated protein kinase pathway in the trascriptional activation of p53 on genotoxic stress by chemotherapeutic agents. Cancer Res 2000, 60(May 1 (9)):2464-2472.
18. Greenberg A.K., Basu S., Hu J., Yie T.A., Tchou-Wong K.M., Rom W.N., et al. Selective p38 activation in human non-small cell lung cancer. Am J Respir Cell Mol Biol 2002, 26(May (5)):558-564.
19. English J.M., Cobb M.H. Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci 2002, 23(1):40-45.
20. Badger A.M., Bradbeer J.N., Votta B., Lee J.C., Adams J.L., Griswold D.E. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 1996, 279(December (3)):1453-1461.
21. Dominguez C., Powers D.A., Tamayo N. p38 MAP kinase inhibitors: many are made, but few are chosen. Curr Opin Drug Discov Devel 2005, 8(July (4)):421-430.
22. Young P.R., McLaughlin M.M., Kumar S., Kassis S., Doyle M.L., McNulty D., et al. Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J Biol Chem 1997, 272:12116-12121.
23. Wilson K.P., McCaffrey P.G., Hsiao K., Pazhanisamy S., Galullo V., Bemis G.W., et al. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem Biol 1997, 4:423-431.
24. Bergstralh D.T., Ting J.P. Microtubule stabilizing agents: their molecular signaling consequences and the potential for enhancement by drug combination. Cancer Treat Rev 2006, 32(May (3)):166-179.
25. Dong Q.G., Sciabas G.M., Fujioka S., Schmidt C., Peng B., Wu T., et al. The function of multiple IkappB: NF-kappaB complexes in the resistance of cancer cells to taxol-induced apoptosis. Oncogene 2002, 21(September (42)):6510-6519.
26. Osaki S., Nakanishi Y., Pei X.H., Ueno H., Hara N. Transfer of IkappaBalpha gene increase the sensitivity of paclitaxel mediated with caspase 3 activation in human lung cancer cell. J Exp Clin Cancer Res 2003, 22(March (1)):69-75.
27. Mabuchi S., Ohmichi M., Nishio Y., Hayasaka T., Kimura A., Ohta T., et al. Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Clin Cancer Res 2004, 10(November (22)):7645-7654.
28. Liu G.H., Wang S.R., Wang B., Kong B.H. Inhibition of nuclear factor-kappaB by an antioxidant enhances paclitaxel sensitivity in ovarian carcinoma cell line. Int J Gynecol Cancer 2006, 16(September-October (5)):1777-1782.
29. Gawlitta D., Oomens G.W., Baaijens F.P., Bouten C.V. Evaluation of a continuous quantification method of apoptosis and necrosis in tissue culture. Cytotechnology 2004, 46(October (2-3)):139-150.
30. Chen Y.R., Tan T.H. Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene 1998, 17(July (2)):173-178.
31. Squires M.S., Hudson E.A., Howells L., Sale S., Houghton C.E., Jones J.L., et al. Relevance of mitogen activated protein kinase (MAPK) and phosphotidylinositol-3-kinase/protein kinase B (PI3K/PKB) pathways to induction of apoposis by curcumin in breast cells. Biochem Pharmacol 2003, 65(February (3)):361-376.
32. Chen Y.R., Tan T.H. The c-Jun N-terminal kinase pathway and apoptotic signaling (review). Int J Oncol 2000, 16(April (4)):651-662.
33. Davies S.P., Reddy H., Caivano M., Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000, 351(October (1)):95-105.
34. Bost F., McKay R., Bost M., Potapova O., Dean N.M., Mercola D. The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A459 lung carinoma cells. Mol Cell Biol 1999, 19(March (3)):1938-1949.
35. Bost F., McKay R., Dean N., Mercola D. The JUN kinase/stress-activated protein kinase pathway is required for epidermal growth factor stimulation of growth of human A549 lung carcinoma cells. J Biol Chem 1997, 272(December (52)):33422-33429.
36. Bain J., McLauchlan H., Elliot M., Cohen P. The specificities of protein kinase inhibitors: an update. Biochem J 2003, 371(April):199-204.
37. Craig R., Larkin A., Mingo A.M., Thuerauf D.J., Andrews C., McDonough P.M., et al. p38 MAPK and NF-kappaB collaborate to incude interleukin-6 gene expression and release. Evidence for a cytoprotective autocrince signaling pathway in a cardiac myoctye model system. J Biol Chem 2000, 275(August (31)):23814-23824.
38. Singer C.A., Baker K.J., McCaffrey A., AuCoin D.P., Dechert M.A., Gerthoffer W.T. p38 MAPK and NF-kappaB mediate COX-2 expression in human airway myocytes. Am J Physiol Lung Cell Mol Physiol 2003, 285(November (5)):L1087-L1098.
39. Selvendiran K., Tong L., Vishwanath S., Bratasz A., Trigg N.J., Kutala V.K., et al. EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression. J Biol Chem 2007, 282(September (39)):28609-28618.
40. Fabian M.A., Biggs W.H., Treiber D.K., Atteridge C.E., Azimioara M.D., Benedetti M.G., et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005, 23(March (3)):329-336.